» Articles » PMID: 1747017

Volunteers for Biomedical Research. Recruitment and Screening of Normal Controls

Overview
Specialty Psychiatry
Date 1991 Nov 1
PMID 1747017
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

We examined the process of accruing healthy control subjects for biomedical research on brain function. Of 1670 responders to newspaper advertising, 23.1% were uninterested when learning more about the studies, and 50.9% of those remaining were found by structured telephone screening to meet exclusionary criteria for having a history of psychiatric, neurologic, or medical disease that might affect brain function. Of 312 volunteers passing the telephone screening who came to an in-person evaluation by a physician and agreed to participate, 49.7% were found to meet exclusionary criteria, and only 157 were admitted to the study. This underscores the importance of attending to the issue of screening and assessment of "normal volunteers." Alternative strategies should be considered for enriching the pool.

Citing Articles

Utilization of the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Measure-Adult to Screen Healthy Volunteers for Research Studies.

Mahoney M, Farmer C, Sinclair S, Sung S, Dehaut K, Chung J Psychiatry Res. 2020; 286:112822.

PMID: 32086029 PMC: 7382979. DOI: 10.1016/j.psychres.2020.112822.


Why knowing healthy controls matters.

Pavletic A Int J Clin Pract. 2019; 74(1):e13424.

PMID: 31573729 PMC: 6980973. DOI: 10.1111/ijcp.13424.


Sex-Dependent Association of Perigenual Anterior Cingulate Cortex Volume and Migration Background, an Environmental Risk Factor for Schizophrenia.

Akdeniz C, Schafer A, Streit F, Haller L, Wust S, Kirsch P Schizophr Bull. 2017; 43(4):925-934.

PMID: 28969352 PMC: 5472165. DOI: 10.1093/schbul/sbw138.


Safety, Science, or Both? Deceptive Healthy Volunteers: Psychiatric Conditions Uncovered by Objective Methods of Screening.

Pavletic A, Pao M Psychosomatics. 2017; 58(6):657-663.

PMID: 28651795 PMC: 5680154. DOI: 10.1016/j.psym.2017.05.001.


CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trials.

M Penas-Lledo E, LLerena A Br J Clin Pharmacol. 2013; 77(4):673-83.

PMID: 24033670 PMC: 3971983. DOI: 10.1111/bcp.12227.